Retrospective evaluation of an observational cohort by the Central and Eastern Europe Network Group shows a high frequency of potential drug-drug interactions among HIV-positive patients receiving treatment for coronavirus disease 2019 (COVID-19)
| Autor: | Marta Vasyliev, Arjan Harxhi, Euroguideliness in Central, Antonija Verhaz, Deniz Gökengin, Kerstin Kase, Justyna D. Kowalska, Antonios Papadopoulus, Raimonda Matulionyte, Josip Begovac, Cristiana Oprea, Sam Hofman, Sergii Antoniak, Botond Lakatos, Anna Vassilenko, N. Rukhadze, Nina Yancheva, Gordana Dragovic, David Jilich, Lukas Fleischhans, Piotr Wasilewski |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Adult
Male medicine.medical_specialty Anti-HIV Agents HIV Infections Emtricitabine Tenofovir alafenamide 03 medical and health sciences 0302 clinical medicine Internal medicine HIV Seropositivity medicine Humans Pharmacology (medical) Drug Interactions 030212 general & internal medicine HIV combination antiretroviral therapy coronavirus disease 2019 (COVID-19) drug-drug interaction severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Tenofovir Retrospective Studies 0303 health sciences Reverse-transcriptase inhibitor 030306 microbiology business.industry Elvitegravir SARS-CoV-2 Health Policy Adenine Lamivudine virus diseases Middle Aged 3. Good health COVID-19 Drug Treatment Eastern european Infectious Diseases Cohort Reverse Transcriptase Inhibitors Female business medicine.drug Cohort study |
| Popis: | Objectives: The aim of this international multicentre study was to review potential drug- drug interactions (DDIs) for real-life coadministration of combination antiretroviral therapy (cART) and coronavirus disease 2019 (COVID-19)-specific medications. Methods: The Euroguidelines in Central and Eastern Europe Network Group initiated a retrospective, observational cohort study of HIV-positive patients diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Data were collected through a standardized questionnaire and DDIs were identified using the University of Liverpool's interaction checker. Results: In total, 524 (94.1% of 557) patients received cART at COVID-19 onset: 117 (22.3%) were female, and the median age was 42 (interquartile range 36-50) years. Only 115 (21.9%) patients were hospitalized, of whom 34 required oxygen therapy. The most frequent nucleoside reverse transcriptase inhibitor (NRTI) backbone was tenofovir disoproxil fumarate (TDF)/tenofovir alafenamide (TAF) with lamivudine or emtricitabine (XTC) (79.3%) along with an integrase strand transfer inhibitor (INSTI) (68.5%), nonnucleoside reverse transcriptase inhibitor (NNRTI) (17.7%), protease inhibitor (PI) (13.7%) or other (2.5%). In total, 148 (28.2%) patients received COVID-19-specific treatments: corticosteroids (15.7%), favipiravir (7.1%), remdesivir (3.1%), hydroxychloroquine (2.7%), tocilizumab (0.6%) and anakinra (0.2%). In total, 62 DDI episodes were identified in 58 patients (11.8% of the total cohort and 41.9% of the COVID-19-specific treatment group). The use of boosted PIs and elvitegravir accounted for 43 DDIs (29%), whereas NNRTIs were responsible for 14 DDIs (9.5%). Conclusions: In this analysis from the Central and Eastern European region on HIV-positive persons receiving COVID-19-specific treatment, it was found that potential DDIs were common. Although low-dose steroids are mainly used for COVID-19 treatment, comedication with boosted antiretrovirals seems to have the most frequent potential for DDIs. In addition, attention should be paid to NNRTI coadministration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|